Janus Kinase (JAK) Inhibitor
Ruxolitinib + Panobinostat for Myelofibrosis
This trial is looking at the safety of long-term treatment with ruxolitinib alone or in combination with panobinostat in patients who have previously participated in a study sponsored by Novart
PARP Inhibitor
Veliparib + Topotecan ± Carboplatin for Leukemia
This trial is studying the side effects and best dose of veliparib when given with topotecan hydrochloride and carboplatin in treating patients with relapsed or refractory acute leukemia, high-risk myelodysplasia, or aggressive myeloproliferative disorders.
Poly (ADP-ribose) polymerase (PARP) inhibitor
Pacritinib + Talazoparib for Myeloproliferative Disorders
This trial is a study to find the appropriate dosage of talazoparib when given with pacritinib, a standard treatment. The goal is to determine the maximum tolerated dosage and the recommended
Curcumin Supplement for Myelodysplastic Syndrome and Myeloproliferative Disorders
This trial looks at how a curcumin supplement can reduce inflammation and symptoms in patients with CCUS, LR-MDS, and MPN. Curcumin has anti-inflammatory and anti-cancer properties and has been studied for various diseases.
LSD1 Inhibitor
Bomedemstat for Polycythemia Vera
This trial tests a pill called bomedemstat for patients with polycythemia vera, a condition with too many red blood cells. The pill works by blocking an enzyme to reduce red blood cells and improve symptoms like an enlarged spleen.
RNAi
SLN124 for Polycythemia Vera
This trial is testing a new drug called SLN124 in adults with Polycythemia Vera, a condition where the body makes too many red blood cells. The study aims to see if SLN124 is safe and effective. Researchers will also look at how the drug moves through and affects the body.
Popular Filters
Trials for Myelofibrosis Patients
Antioxidant
N-Acetylcysteine for Myeloproliferative Disorders
This trial is testing the best dose of N-acetylcysteine for patients with certain types of blood cancers. The medication helps reduce inflammation and protect cells, which might be beneficial for these patients. N-acetylcysteine (NAC) has been studied for its potential to prevent heart damage caused by certain cancer treatments and reduce flare-ups in chronic lung disease.
Alkylating agents
Reduced-Intensity Conditioning for Blood Cancers
This trial is looking at whether a less intense conditioning regimen of radiation therapy and chemotherapy prior to a hematopoietic stem cell transplant reduces the rate of treatment-related mortality.
Anti-metabolites
Decitabine + JAK Inhibitors for Advanced Myeloproliferative Disorders
This trial looks at whether a combination of decitabine, ruxolitinib, and fedratinib may be more effective than chemotherapy or no treatment in patients with myeloproliferative neoplasms.
Alkylating agents
Topotecan + Carboplatin + Veliparib for Leukemia
This trial is testing how well topotecan hydrochloride, carboplatin, and veliparib work in treating patients with myeloproliferative disorders and acute myeloid leukemia or chronic myelomonocytic leukemia.
Trials for PV Patients
Antioxidant
N-Acetylcysteine for Myeloproliferative Disorders
This trial is testing the best dose of N-acetylcysteine for patients with certain types of blood cancers. The medication helps reduce inflammation and protect cells, which might be beneficial for these patients. N-acetylcysteine (NAC) has been studied for its potential to prevent heart damage caused by certain cancer treatments and reduce flare-ups in chronic lung disease.
Alkylating agents
Reduced-Intensity Conditioning for Blood Cancers
This trial is looking at whether a less intense conditioning regimen of radiation therapy and chemotherapy prior to a hematopoietic stem cell transplant reduces the rate of treatment-related mortality.
Anti-metabolites
Decitabine + JAK Inhibitors for Advanced Myeloproliferative Disorders
This trial looks at whether a combination of decitabine, ruxolitinib, and fedratinib may be more effective than chemotherapy or no treatment in patients with myeloproliferative neoplasms.
Hepcidin Mimetic
Hepcidin Mimetic for Polycythemia Vera
This trial tests PTG-300, a new medication, in patients with polycythemia vera who need regular blood removal. PTG-300 aims to keep red blood cell levels in check, reducing the need for frequent blood removal.
Phase 3 Trials
Epigenetic Modulator
Bomedemstat for Blood Disorders
"This trial aims to continue monitoring participants who have been taking bomedemstat for a while to gather information on its long-term safety and effectiveness. Participants must have been using bomedemstat for at
Interferon
ECLIPSE PV / A22-203
This trial tests a medication called ropeginterferon alfa-2b-njft in adults with polycythemia vera, a type of blood cancer. The goal is to see how well it works and how safe it is. The medication helps the immune system control abnormal blood cells to prevent serious health issues. Ropeginterferon alfa-2b is a new form of treatment recently shown to be safe and effective in polycythemia vera.
JAK2 Inhibitor
Pacritinib for Myelofibrosis
This trial is testing a new drug, pacritinib, to see if it is better than the current standard of care for treating patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis who have severe thrombocytopenia (low platelet count). 399 patients will be enrolled and randomly assigned to either pacritinib or the current standard of care. The primary outcome measure is spleen response rate.
Protein Therapeutics
Luspatercept for Myelofibrosis
This trial is studying how well luspatercept works in treating patients with myeloproliferative neoplasm-associated myelofibrosis and anemia who are on concomitant Janus kinase 2 inhibitor therapy and who require red blood cell count transfusions.
Trials With No Placebo
Antioxidant
N-Acetylcysteine for Myeloproliferative Disorders
This trial is testing the best dose of N-acetylcysteine for patients with certain types of blood cancers. The medication helps reduce inflammation and protect cells, which might be beneficial for these patients. N-acetylcysteine (NAC) has been studied for its potential to prevent heart damage caused by certain cancer treatments and reduce flare-ups in chronic lung disease.
Alkylating agents
Reduced-Intensity Conditioning for Blood Cancers
This trial is looking at whether a less intense conditioning regimen of radiation therapy and chemotherapy prior to a hematopoietic stem cell transplant reduces the rate of treatment-related mortality.
Anti-metabolites
Decitabine + JAK Inhibitors for Advanced Myeloproliferative Disorders
This trial looks at whether a combination of decitabine, ruxolitinib, and fedratinib may be more effective than chemotherapy or no treatment in patients with myeloproliferative neoplasms.
Frequently Asked Questions
Introduction to polycythemia vera
What are the top hospitals conducting polycythemia vera research?
When it comes to conducting clinical trials for polycythemia vera, several top hospitals are leading the way in advancing our understanding and treatment of this rare blood disorder. One such institution is The University of Texas MD Anderson Cancer Center in Houston. With five active trials focused on polycythemia vera and a total of seven trials conducted to date, MD Anderson has been at the forefront of research for this condition since their first recorded trial in 2017.
Similarly, Washington University School of Medicine in Saint Louis has also made significant contributions to polycythemia vera research. This esteemed medical school currently has five ongoing clinical trials dedicated to studying the disorder and has conducted a total of five trials thus far since their initial study was recorded in 2019.
The University of Colorado Cancer Center located in Aurora is another prominent hospital actively involved in improving outcomes for patients with polycythemia vera. They currently have four active clinical trials focusing on this condition, building upon their legacy that began with their first recorded trial back in 2015.
In the Bronx, Montefiore Medical Center stands as a vital hub for conducting cutting-edge studies related to polycythemia vera. With four ongoing clinical trials dedicated to exploring new treatments and management strategies, Montefiore Medical Center continues its commitment towards advancements against this disease after recording its first trial just three years ago.
Finally, we turn our attention to Icahn School of Medicine at Mount Sinai situated within bustling New york City. This renowned institution showcases an impressive history with eighteen completed polycythemia vera clinical trials alongside four presently underway endeavors tackling various aspects pertaining to this blood disorder that were initiated by them over a decade ago during2007.Their contribution underscores the significance placed on understanding and fighting against polycythemia vera throughout time
These top hospitals across different locations not only provide hope for those affected by polycythemia vera but also symbolize the collective efforts being made by the medical community to conquer rare diseases. Each trial conducted brings us closer to advancements in treatment and improved quality of life for patients with this condition.
Which are the best cities for polycythemia vera clinical trials?
When it comes to polycythemia vera clinical trials, several cities emerge as top contenders. Houston, Texas leads the way with 26 active trials focusing on promising treatments like parsaclisib, KRT-232, and FEDRATINIB. New york City follows closely behind with 21 ongoing studies exploring interventions such as FEDRATINIB, Pelabresib, and ACE-536. Meanwhile, Saint Louis in Missouri boasts 12 active trials investigating treatments like FEDRATINIB and KRT-232. Toronto in Ontario and Los Angeles in California both have 10 active trials each studying various treatment options for polycythemia vera. These cities provide individuals suffering from this condition access to cutting-edge clinical research that holds promise for improved outcomes and better management of their disease.
Which are the top treatments for polycythemia vera being explored in clinical trials?
Promising treatments are currently being explored in clinical trials for polycythemia vera. One such treatment is KRT-232, which has shown potential in four active trials and marks its first listing in 2019. Another contender is parsaclisib, with two ongoing trials since its introduction in 2021. Last but not least, bomedemstat joins the race as a newcomer with one active trial and a debut listing scheduled for 2023. As researchers delve into these innovative approaches to tackle polycythemia vera, new avenues of hope may soon open up for patients affected by this condition.
What are the most recent clinical trials for polycythemia vera?
Promising advancements have emerged in the field of polycythemia vera, offering hope to those affected by this condition. Notably, clinical trials investigating bomedemstat and reparixin have shown encouraging results. Bomedemstat, in particular, has entered Phase 2 trials and demonstrates potential as a treatment option. Similarly, research on reparixin also indicates positive outcomes for polycythemia vera patients. These recent developments reflect the ongoing efforts to improve therapeutic strategies for managing this disease effectively. With these promising studies underway, individuals with polycythemia vera can look forward to enhanced treatment options on the horizon.
What polycythemia vera clinical trials were recently completed?
Recently, several clinical trials have concluded, bringing us closer to advancements in the treatment of polycythemia vera. In July 2021, Incyte Corporation completed a trial examining the potential of itacitinib as a therapeutic option for this condition. John Mascarenhas also sponsored a trial that reached completion in February 2019, investigating the efficacy of AVID200. Furthermore, Imago BioSciences conducted a trial on IMG-7289 which was completed in July 2017. While earlier but worth mentioning is the completion of a trial on Smac Mimetic LCL161 by M.D. Anderson Cancer Center back in December 2014. These valuable research endeavors shed light on potential breakthroughs and offer hope to individuals living with polycythemia vera.